Catalog No.
Product Name
Application
Product Information
Citations
-
CDK Inhibitor
BS-194 is a selective and potent cyclin-dependent kinase (CDK) inhibitor, primarily targeting CDK2, CDK1, CDK5, CDK7, and CDK9 with IC50 values of 3, 30, 30, 250, and 90 nM, respectively. This compound effectively inhibits the proliferation of cancer cells, making it a valuable tool for cancer research. BS-194 is particularly relevant for studies focusing on breast and colon cancer, providing insights into cellular mechanisms and potential therapeutic strategies. -
CDK7/12 Inhibitor
CDK7/12-IN-1 is a selective inhibitor of cyclin-dependent kinases 7 and 12, exhibiting IC50 values of 3 nM and 277 nM, respectively. By inhibiting CDK7 and CDK12, this compound effectively disrupts key signaling pathways involved in tumor growth and proliferation. CDK7/12-IN-1 is a valuable tool for researchers investigating the role of these kinases in cancer biology and therapeutic development. -
Cdk5 Peptide Inhibior
Cdk5i peptide is an inhibitor targeting cyclin-dependent kinase 5 (CDK5), displaying a strong binding affinity for the CDK5/p25 complex with a dissociation constant (Kd) of 0.17 μM. This peptide effectively disrupts the interaction between CDK5 and p25, subsequently reducing the kinase activity of the CDK5/p25 complex. Cdk5i peptide is particularly relevant for research into neurodegenerative diseases, providing a valuable tool for elucidating the role of CDK5 in neuronal function and pathology. -
CDK Inhibitor
Zeltociclib is a potent cyclin-dependent kinase inhibitor that demonstrates significant antitumor activity. By selectively inhibiting CDK activity, it effectively disrupts cell cycle progression, making it a valuable candidate for cancer research. Zeltociclib is particularly relevant in studies examining therapeutic strategies against various malignancies. -
PROTAC CDK9 Degrader
PROTAC CDK9 degrader-9 is a selective and potent degrader designed to target cyclin-dependent kinase 9 (CDK9) via PROTAC technology. This compound facilitates the targeted degradation of CDK9, thereby modulating transcriptional regulation and influencing cell proliferation. It is particularly useful in anti-cancer research, where the inhibition of CDK9 can lead to suppression of oncogenic pathways. -
CDK7 Inhibitor
CDK7-IN-2 is a selective inhibitor of cyclin-dependent kinases 7 (CDK7), which plays a critical role in cell cycle regulation and transcriptional activation. By targeting CDK7, this compound disrupts the phosphorylation of the Rbpl subunit of RNA Polymerase II, thereby modulating gene expression. CDK7-IN-2 is valuable for research applications focused on cancer biology, particularly in studying aggressive and treatment-resistant tumor types. -
CDK Inhibitor
CDK9-IN-11 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), a critical regulator of transcription and cell cycle progression. This compound serves as a ligand for the PROTAC CDK9 Degrader-1, facilitating targeted degradation of CDK9. CDK9-IN-11 exhibits significant biological activity in cancer research, making it a valuable tool for studies focused on cell proliferation and transcriptional regulation. -
Cdk7 Inhibitor
YKL-1-116 is a selective and covalent inhibitor of cyclin-dependent kinase 7 (Cdk7), exhibiting enhanced potency compared to THZ1 against both Cdk7 wild type (Cdk7WT) and Cdk7 activated site mutant (Cdk7as). Importantly, YKL-1-116 does not inhibit Cdk9, Cdk12, or Cdk13, making it a valuable tool for studying Cdk7's role in transcriptional regulation and cellular processes. This compound can be utilized in research applications exploring the therapeutic potential of targeting Cdk7 in cancer and other diseases. -
CDK1 Inhibitor
CDK1-IN-2 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), exhibiting an IC50 value of 5.8 μM. This compound is primarily utilized in research focusing on cell cycle regulation and cancer therapeutics. By inhibiting CDK1 activity, CDK1-IN-2 serves as a valuable tool for studying the effects of cell proliferation and apoptosis in various cancer models. -
CCNE1:CDK2 Complex Inhibitor
CDK2-IN-31 is a potent inhibitor of the CCNE1:CDK2 complex, exhibiting an IC50 of 0.13 μM. It binds to a unique allosteric pocket at the interface of CCNE1 and CDK2, leading to significant structural changes in the CDK2 A-loop that disrupt its active conformation and hinder substrate binding. This compound effectively inhibits the phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells and disrupts the coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 is valuable for research investigating ovarian cancer mechanisms and potential therapeutic targets. -
CDK Inhibitor
CDK9-IN-12 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting optimal inhibitory activity with an IC50 value of 5.41 nM. Its ability to selectively target CDK9 makes it a valuable tool in research applications focused on transcriptional regulation and cancer therapy. This compound can aid in elucidating the role of CDK9 in various cellular processes and contribute to the development of novel therapeutic strategies. -
CDK2 Inhibitor
PNU-292137 is a potent inhibitor of Cyclin-Dependent Kinase 2 (CDK2), with IC50 values of 37 nM for the CDK2/cyclin A complex and 92 nM for the CDK2/cyclin E complex. This compound interacts with the hydrophobic pocket located within the ATP binding site of CDK2, effectively hindering tumor cell proliferation in human colon and prostate cancer cell lines. Additionally, PNU-292137 demonstrates significant antitumor activity in vivo, evidenced by a tumor growth inhibition greater than 50% in mouse xenograft models, making it a valuable tool for cancer research. -
CDK Inhibitor
Eciruciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), primarily targeting CDK2, CDK4, and CDK6. It demonstrates significant antineoplastic activity, making it a valuable tool for cancer research. This compound is employed in studies aimed at understanding cell cycle regulation and developing targeted therapies for various malignancies. -
PROTAC CDK9 degrader
PROTAC CDK9 degrader-2, a selective degrader of cyclin-dependent kinase 9 (CDK9), utilizes a PROTAC mechanism involving a natural product ligand, Wogonin, which targets the ubiquitin E3 ligase Cereblon (CRBN). With an IC50 of 17 μM in MCF-7 cell lines, this compound demonstrates potent activity in the degradation of CDK9, making it a valuable reagent for research applications focused on CDK9-related pathways in cancer biology and therapeutic development. -
Cdk2/9 Inhibitor
CK7 is a potent inhibitor of cyclin-dependent kinases Cdk2 and Cdk9. It demonstrates significant biological activity in modulating cell cycle progression and transcriptional regulation. This reagent is particularly useful in research applications focused on cancer biology and the development of novel therapeutics targeting the cell cycle. Additionally, CK7 serves as a synthetic precursor for the production of Nek1 inhibitors BSc5231 and BSc5367. -
CDK4/6 Inhibitor
CGP-82996 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates IC50 values of 1.5 μM, 5.6 μM, and 25 μM against CDK4/cyclin D1, CDK6/cyclin D1, and Cdk5/p35, respectively. This compound effectively induces apoptosis in U2OS cancer cells, making it a valuable tool in cancer research to study the modulation of cell cycle progression and cancer cell viability. -
CDK Inhibitor
CDK-IN-6 is a pyrazolo[1,5-a]pyrimidine compound that functions as a cyclin-dependent kinase (CDK) inhibitor. This compound exhibits significant anticancer activity by hindering cell cycle progression, particularly in malignant cells. CDK-IN-6 is utilized in research to explore pathways involved in cancer proliferation and may serve as a valuable tool for investigating therapeutic strategies targeting CDK regulation in various tumors. -
CDK Inhibitor
N9-Isopropylolomoucine is a selective inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CCNB1/CDK1. It plays a critical role in regulating cell cycle progression and mitotic processes. This compound is valuable in cancer research for studying cell proliferation and exploring therapeutic strategies that disrupt tumor growth by targeting CDK activity. -
CDK9/cyclin T1 Inhibitor
CAN508 is a potent ATP-competitive inhibitor of the CDK9/cyclin T1 complex, displaying an IC50 of 0.35 μM. This compound demonstrates a remarkable 38-fold selectivity for CDK9/cyclin T over other cyclin-dependent kinases, making it a valuable tool for investigating transcriptional regulation. Its antitumor activity positions CAN508 as a relevant candidate for research into cancer therapeutics and related signaling pathways. -
CDK4/6 Inhibitor
CDK4/6-IN-12 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates significant enzymatic inhibitory activity, with IC50 values of 592.3 nM for CDK4 and 3090 nM for CDK6. This compound is valuable for cancer research, particularly in studies exploring cell cycle regulation and therapeutic strategies targeting CDK4/6 in tumor cells. -
CDK12 Inhibitor
CDK12-IN-5 is a selective inhibitor of cyclin-dependent kinase 12 (CDK12), exhibiting a potent inhibitory activity with an IC50 of 23.9 nM in the presence of high ATP (2 mM). This compound shows no significant inhibition against CDK2/Cyclin E or CDK9/Cyclin T1, with IC50 values of 173 μM and 127 μM, respectively, under the same conditions. CDK12-IN-5 is valuable for studies investigating the role of CDK12 in transcriptional regulation and its implications in cancer research. -
CDK Inhibitor
CDK5-IN-1 is a selective inhibitor of cyclin-dependent kinase 5 (CDK5), exhibiting an inhibitory concentration (IC50) of less than 10 nM. This compound demonstrates over 100-fold specificity for CDK5 compared to CDK2, making it a valuable tool for studying CDK5-related pathways. CDK5-IN-1 is applicable in research on kidney diseases and offers insights into the molecular mechanisms governing renal function and pathology. -
CDK2 Inhibitor
CDK2-IN-13 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 value of 12 µM. This compound is primarily utilized in cancer research to study the role of CDK2 in cell cycle regulation and tumor proliferation. Its ability to modulate CDK2 activity makes it a valuable tool for investigating potential therapeutic strategies in oncology. -
CDK14/CDK16 Inhibitor
FMF-04-159-R is an inhibitor of cyclin-dependent kinases CDK14 and CDK16, exhibiting IC50 values of 5.9 nM and 139.1 nM, respectively. This compound is primarily utilized in research to explore the roles of CDK14 and CDK16 in cell cycle regulation and transcriptional control. Its selective inhibition may provide insights into therapeutic strategies for diseases linked to dysregulated kinase activity. -
CDK4/6 Inhibitor
CDK4/6-IN-9 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting an IC50 of 905 nM for the CDK6/cyclin D1 complex. This compound demonstrates significant potential in the investigation of multiple myeloma (MM) biology and therapeutic strategies. It is designed to facilitate research focused on cell cycle regulation and the oncogenic pathways associated with MM. -
CDK2 Degrader
(R)-CDK2 Degrader 6 is a cereblon-based molecular glue degrader specifically targeting cyclin-dependent kinase 2 (CDK2). It functions by inducing ubiquitination and subsequent proteasomal degradation of CDK2, with a DC50 value of 27 nM. This compound is suitable for cancer research applications, providing a valuable tool for studying CDK2-related pathways and therapeutic interventions. -
CDK Inhibitor
(2S,3R)-Voruciclib hydrochloride is a selective inhibitor of cyclin-dependent kinases (CDKs), demonstrating potent activity against various CDK isoforms. This compound is primarily used in the study of cell cycle regulation and cancer biology, providing insights into mechanisms of proliferation and tumor growth. Its oral bioavailability makes it a valuable tool for in vivo research applications in cancer therapeutics. -
CDK Inhibitor
Tanuxiciclib is a selective cyclin-dependent kinase (CDK) inhibitor that targets multiple CDK family members. It exhibits potent antitumor activity through the inhibition of cell cycle progression, making it a valuable tool in cancer research. This compound is utilized in studies investigating cell proliferation, apoptosis, and the mechanisms of cancer cell survival, offering potential insights into novel therapeutic strategies. -
CDK4 Inhibitor
NSC 625987 is a potent CDK4 inhibitor, exhibiting an IC50 of 0.2 μM for the CDK4:cyclin D1 complex. This compound demonstrates more than 500-fold selectivity for CDK4 compared to CDK2, making it a valuable tool for studying cell cycle regulation and cancer biology. Its specificity and efficacy make NSC 625987 suitable for research applications aimed at understanding CDK4's role in tumor proliferation and potential therapeutic strategies. -
CDK7 Inhibitor
SHR5428 is a selective and noncovalent inhibitor of cyclin-dependent kinase 7 (CDK7), exhibiting potent enzymatic activity with an IC50 of 2.3 nM. This compound effectively inhibits cellular activity in triple-negative breast cancer models, specifically in MDA-MB-468 cells, with an IC50 of 6.6 nM. SHR5428 is suitable for research applications involving cell cycle regulation and therapeutic development for aggressive breast cancer forms. -
CDK9 PROTAC
PROTAC CDK9 degrader-7 is a designed degradate that specifically targets cyclin-dependent kinase 9 (CDK9). This compound facilitates the degradation of CDK9 through the proteasomal pathway, effectively reducing its cellular levels. Its biological activity makes it a valuable tool for research applications focused on investigating CDK9's role in transcription regulation and its implications in cancer therapy. -
CDK4 Inhibitor
ZDLD20 is a selective inhibitor of CDK4, exhibiting an IC50 value of 6.51 μM. This β-carboline compound demonstrates significant anti-cancer properties, particularly against HCT116 cells, by inhibiting colony formation, invasion, and migration. Additionally, ZDLD20 promotes apoptosis and induces G1 phase cell cycle arrest, making it a valuable tool for cancer research and therapeutic development. -
CDK2 (Cyclin dependent kinase 2) Inhibitor
CDK2-IN-40 is a potent inhibitor of Cyclin-dependent kinase 2 (CDK2), demonstrating effective inhibition of the CDK2/Cyclin E1 complex with an IC50 value of ≤ 10 nM. This compound plays a significant role in regulating cell cycle progression and is valuable for research applications related to cancer therapy and cellular proliferation studies. CDK2-IN-40 can be utilized to explore the implications of CDK2 inhibition in various biological contexts. -
CDK7 Inhibitor
LDC3140 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of less than 5 nM. By targeting CDK7, LDC3140 disrupts cell cycle regulation, resulting in cell cycle arrest and reduced proliferation of tumor cells. This compound serves as a valuable tool for research focused on cancer therapeutics and the mechanistic understanding of cell cycle dynamics in cancer biology. -
CDK Inhibitor
CDK9-IN-10 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), effectively targeting the transcriptional regulation pathways. This compound serves as a crucial ligand for the PROTAC CDK9 degrader-2, facilitating targeted degradation of CDK9 in cellular studies. Its applications include investigations into oncogenic processes and transcriptional dysregulation, making it a valuable tool for cancer research and drug discovery. -
CDK9 Inhibitor
CDK9-IN-14 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 value of 6.92 nM. This compound demonstrates significant inhibitory activity against MV4;11 cells and exhibits efficacy in in vivo tumor models. Additionally, CDK9-IN-14 shows favorable selectivity and a low toxicity profile, making it suitable for various cancer research applications aimed at targeting transcriptional regulation pathways. -
CDK Inhibitor
Atuveciclib S-Enantiomer is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9). With an IC50 of 16 nM, it effectively inhibits the CDK9/CycT1 complex, playing a crucial role in regulating transcription and cell cycle progression. This compound is primarily utilized in research applications targeting cancer therapeutics and studying transcriptional regulation mechanisms. -
CDK7 Inhibitor
CDK7-IN-1 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 100 nM. This compound effectively modulates CDK7 activity, disrupting cell cycle progression and transcription regulation. CDK7-IN-1 is suitable for research applications related to cancer biology and therapeutic development targeting aberrant cell proliferation. -
CDK7 Inhibitor
IV-361 is a selective cyclin-dependent kinase 7 (CDK7) inhibitor with a Ki value of less than 50 nM. This compound exhibits significant anti-cancer activity, making it a valuable tool for researchers investigating cancer cell proliferation and survival pathways. IV-361's specificity for CDK7 allows for in-depth studies of its role in transcription regulation and potential therapeutic applications in cancer treatment. -
CDK4 Inhibitor
Cimpuciclib tosylate is a potent selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 0.49 nM. Its strong inhibitory activity is associated with anti-tumor effects and promotes cell cycle arrest in cancer research. This compound is valuable for studies focused on tumor proliferation and therapeutic strategies targeting CDK4 in various cancer types. -
CDK4/6 Inhibitor
CDK4/6-IN-18 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates the ability to effectively inhibit ionizing radiation-induced DNA damage in cellular models. This compound is a valuable tool for research focused on cancer biology and therapies that target the cell cycle and DNA damage response pathways. -
CDK6 Inhibitor
CDK6-IN-1 is a selective inhibitor of cyclin-dependent kinase 6 (CDK6), functioning primarily by impeding cell growth and promoting G1-phase cell cycle arrest. This compound has significant implications in cancer research, particularly in studies targeting cell proliferation and tumorigenesis. Its efficacy in modulating cell cycle progression makes it a valuable tool for investigating mechanisms of cancer therapy and the role of CDK6 in malignancies. -
CDK7 Inhibitor
JNJ-3738 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with a Ki value of 21.75 nM. This compound demonstrates potent inhibitory activity in CDK7 wild-type expressing A549 cells, exhibiting a pIC50 of 7.37. JNJ-3738 is primarily utilized in research applications focused on cell cycle regulation, transcriptional control, and cancer biology. -
CDK2 Molecular Glue Degrader
(S)-CDK2 degrader 6 selectively targets cyclin-dependent kinase 2 (CDK2) as a molecular glue degrader. With a DC50 of 166.7 nM over 24 hours, this compound effectively promotes the degradation of CDK2, thereby modulating cell cycle progression. It holds significant potential for applications in breast cancer research, enabling the exploration of therapeutic strategies that involve the regulation of CDK2 activity. -
CDK12 Inhibitor
PPA-037 is a potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12) with oral bioavailability. By inducing the degradation of cyclin K, PPA-037 enhances antiproliferative effects on various tumor cells. This compound holds significant potential for cancer research applications focused on targeting CDK12-related pathways. -
CDK4-Cyclin D1 Kinase Inhibitor
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a tumor suppressor protein that targets CDK4-Cyclin D1 kinase. This peptide effectively binds to CDK4 and CDK6, demonstrating an inhibitory effect on CDK4-cyclin D1 activity with an IC50 of 1.5 μM. Its mechanism of action leads to the blockade of cell cycle progression through the G1 phase, making it a valuable reagent for cancer research and studies focusing on cell cycle regulation. -
Cyclin K Degrader
DS17 is a molecular glue that functions as a potent degrader of cyclin K, exhibiting an EC50 value of 13 nM. This compound is pivotal for cancer research due to its ability to modulate cell cycle dynamics and influence tumor progression. Researchers can utilize DS17 to investigate the therapeutic potential of targeting cyclin K in various malignancies. -
SCDKI Pathway Inhibitor
SNX7 is a selective inhibitor of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. This compound plays a crucial role in studying cellular senescence and various CDKI-related diseases. By targeting the CDKI pathway, SNX7 serves as a valuable tool in cancer research and other conditions where cell cycle regulation is disrupted. -
CDK12/13 Inhibitor
CDK12/13-IN-3 is a selective inhibitor of cyclin-dependent kinases 12 and 13, demonstrating IC50 values of 107.4 nM and 79.4 nM, respectively. This compound effectively inhibits the phosphorylation of Ser2 on the C-terminal domain of RNA polymerase II, leading to DNA damage and downregulation of DNA damage response gene expression. CDK12/13-IN-3 exhibits notable antiproliferative activity against a variety of cancer cell lines and shows significant antitumor effects in mouse models, supported by favorable pharmacokinetic properties, including an oral bioavailability of 53.6%. -
CDK9 Inhibitor
XPW1 is a potent and selective inhibitor of CDK9, a key regulator in transcriptional control linked to cancer progression. This compound exhibits significant anti-tumor activity against clear cell renal cell carcinoma (ccRCC) and demonstrates favorable toxicity profiles. Its unique mechanism of action makes it a valuable tool for research into CDK9's role in cancer biology and therapeutic interventions.
